These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38824222)

  • 1. DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivity.
    Liu Y; Li Z; Zhang J; Liu W; Guan S; Zhan Y; Fang Y; Li Y; Deng H; Shen Z
    Br J Cancer; 2024 Jul; 131(2):243-257. PubMed ID: 38824222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.
    Hsieh FS; Chen YL; Hung MH; Chu PY; Tsai MH; Chen LJ; Hsiao YJ; Shih CT; Chang MJ; Chao TI; Shiau CW; Chen KF
    Mol Oncol; 2017 Aug; 11(8):1035-1049. PubMed ID: 28453226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
    Bollard J; Miguela V; Ruiz de Galarreta M; Venkatesh A; Bian CB; Roberto MP; Tovar V; Sia D; Molina-Sánchez P; Nguyen CB; Nakagawa S; Llovet JM; Hoshida Y; Lujambio A
    Gut; 2017 Jul; 66(7):1286-1296. PubMed ID: 27849562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
    Yang H; Zhao X; Zhao L; Liu L; Li J; Jia W; Liu J; Huang G
    Oncotarget; 2016 Nov; 7(44):72131-72147. PubMed ID: 27708221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lncRNA
    Zhou N; Li S; Wu D; Zhang F; Tang F; Li Y
    DNA Cell Biol; 2021 Oct; 40(10):1278-1289. PubMed ID: 34558987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
    Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
    Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DYNLL1 is hypomethylated and upregulated in a tumor stage- and grade-dependent manner and associated with increased mortality in hepatocellular carcinoma.
    Berkel C; Cacan E
    Exp Mol Pathol; 2020 Dec; 117():104567. PubMed ID: 33171156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
    BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daidzein and Chicory Extract Arrest the Cell Cycle
    Abdel-Hamid NM; Zakaria S; Nawaya RA; Eldomany RA; El-Shishtawy MM
    Recent Pat Anticancer Drug Discov; 2022; 18(2):187-199. PubMed ID: 35319392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway.
    Liu YM; Cao Y; Zhao PS; Wu LY; Lu YM; Wang YL; Zhao JF; Liu XG
    Int J Biol Sci; 2022; 18(2):637-651. PubMed ID: 35002514
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
    Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
    Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRNDE-h transcript/miR-136-5p axis regulates interleukin enhancer binding factor 2 expression to promote hepatocellular carcinoma cell proliferation.
    Shiu TY; Lin HH; Shih YL; Feng AC; Huang HH; Huang TY; Hsieh CB; Chang WK; Hsieh TY
    Life Sci; 2021 Nov; 284():119708. PubMed ID: 34153299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin Y binds and activates CDK4 to promote the G1/S phase transition in hepatocellular carcinoma cells via Rb signaling.
    Chen L; Wang X; Cheng H; Zhang W; Liu Y; Zeng W; Yu L; Huang C; Liu G
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1162-1169. PubMed ID: 33039146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
    Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
    Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and Critical Role of Interleukin Enhancer Binding Factor 2 in Hepatocellular Carcinoma.
    Cheng S; Jiang X; Ding C; Du C; Owusu-Ansah KG; Weng X; Hu W; Peng C; Lv Z; Tong R; Xiao H; Xie H; Zhou L; Wu J; Zheng S
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27556459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
    Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.